Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Join the brightest minds in regulatory at the annual Regulatory Convergence. See the global regulatory community in action. Intensive workshops. Topical sessions. Meet ups with regulators. This is where it all comes together.
With so many global regulation changes, staying informed is a challenge. Join other regulatory professionals as you navigate the gray together.
Updated by a group of distinguished regulatory experts, this new edition is a must-have handbook for regulatory professionals at all levels.
In light of the COVID-19 pandemic, the RAC Board has elected to offer online testing with live online proctoring this summer.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
The RAPS store will be under maintenance Saturday, 13 June between 6 AM and 12 PM EST. Store functionality may be unavailable at times during this window. We apologize for any inconvenience caused during this time.
Posted 30 January 2018 | By Zachary Brennan
The Association for Accessible Medicines' Biosimilars Council says Johnson & Johnson's (J&J) methods for blocking Pfizer's Remicade biosimilar could "serve as a blueprint for every brand name biologic drug maker seeking to maintain monopoly power and profits indefinitely in the face of competition from a lower-priced biosimilar," according to a brief submitted to the US District Court for the Eastern District of Pennsylvania.
At issue is a complaint filed by Pfizer last September arguing that its Remicade biosimilar, known as Inflectra (infliximab-dyyb), has gained just a tiny fraction of market share because of exclusionary contracts that J&J employs to stifle competition.
The Biosimilar Council's brief, which is in opposition to J&J's motion to dismiss Pfizer's complaint, explains how insurers have an economic incentive to accept the type of exclusionary contracts that J&J has used to maintain its dominance in the Remicade market despite these less-expensive biosimilar competitors on the market.
"J&J and other brand companies can leverage their patient bases for other products that enjoy strong brand loyalty by denying rebates to insurance companies for those products unless the insurers agree not to cover the relevant biosimilar," the Council says.
While noting the harm caused by J&J's exclusionary strategy on bringing down the prices of biologics for consumers even after enjoying its years of monopoly, the Council notes that it "is critical at this pivotal time for the fledgling biosimilars industry, and consistent with the overarching purposes of the BPCIA [Biologics Price Competition and Innovation Act], that incentives to develop and market biosimilars remain strong to improve patient access to more affordable prescription drugs."
The brief also notes that this case will be an important precedent to set, especially as Avalere Health has predicted that, "by 2025, seven blockbuster branded biologics that taken together account for 30% of U.S. biologic sales will all be outside the 12-year exclusivity window."
BRIEF OF THE BIOSIMILARS COUNCIL AS AMICUS CURIAE IN OPPOSITION TO DEFENDANTS' MOTION TO DISMISS
Regulatory Focus newsletters
All the biggest regulatory news and happenings.